SHPHF (Sihuan Pharmaceutical Holdings Group) YoY EPS Growth: 140.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHPHF Sihuan Pharmaceutical Holdings Group Ltd SHPHF
60 GF Score
Price $0.12
GF Value $0.18
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sihuan Pharmaceutical Holdings Group YoY EPS Growth?

Sihuan Pharmaceutical Holdings Group SHPHF 60 YoY EPS Growth is 140.00% as of Jun. 2026. GuruFocus rates SHPHF with a GF Score™ of 60/100 and a GF Value™ of $0.18 (Possible Value Trap). The stock has 4 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Sihuan Pharmaceutical Holdings Group's YoY EPS Growth for the quarter that ended in Jun. 2026 was 140.00%.

Sihuan Pharmaceutical Holdings Group's Earnings per Share (Diluted) for the six months ended in Jun. 2026 was $0.00.

Sihuan Pharmaceutical Holdings Group YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Sihuan Pharmaceutical Holdings Group's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sihuan Pharmaceutical Holdings Group YoY EPS Growth Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.69 -555.88 97.42 -300.00 184.38

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.50 -2,700.00 400.00 142.86 140.00
SHPHF
60GF Score
Sihuan Pharmaceutical Holdings Group Ltd SHPHF
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sihuan Pharmaceutical Holdings Group YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Sihuan Pharmaceutical Holdings Group's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(0.0027--0.0032)/ | -0.0032 |
=184.38 %

Sihuan Pharmaceutical Holdings Group's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(0.0036-0.0015)/ | 0.0015 |
=140.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 140.00% mean?
Sihuan Pharmaceutical Holdings Group (SHPHF) has a YoY EPS Growth of 140.00% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Sihuan Pharmaceutical Holdings Group and its competitors.
Is Sihuan Pharmaceutical Holdings Group's YoY EPS Growth too high?
Sihuan Pharmaceutical Holdings Group's current YoY EPS Growth is 140.00%. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's YoY EPS Growth compare to ZTS?
Sihuan Pharmaceutical Holdings Group's YoY EPS Growth of 140.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Drug Manufacturers company?
A good YoY EPS Growth depends on the Drug Manufacturers industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Sihuan Pharmaceutical Holdings Group and its competitors. Sihuan Pharmaceutical Holdings Group's current YoY EPS Growth is 140.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.18, compared to a current price of $0.12 — trading 33.3% below its estimated fair value. The current YoY EPS Growth is 140.00%. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current YoY EPS Growth is 140.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued. The current stock price of $0.12 is trading 33.3% below its estimated GF Value™ of $0.18. GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Possible Value Trap.

Key valuation signals for SHPHF:

  • YoY EPS Growth: 140.00%
  • GF Value™: $0.18 vs. price of $0.12 (33.3% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sihuan Pharmaceutical Holdings Group Business Description

Other Exchanges 00460:Hong KongTEL1:Germany
Address 1 Harbour Road, Convention Plaza, Room 4905, Office Tower, Wanchai, HKG
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
60GF Score

Get the complete analysis for SHPHF

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price
$0.18
GF Value